within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB10_Amrubicin;

model Amrubicin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.1361111111111111e-05,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.054,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.111,
    k12 = 2.2222222222222223e-05,
    k21 = 2.2222222222222223e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Amrubicin</td></tr><tr><td>ATC code:</td><td>L01DB10</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>54.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>40.9</td><td>L/h/m2</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Amrubicin is a synthetic anthracycline antitumor agent used in the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It acts primarily as a topoisomerase II inhibitor. Amrubicin is approved for use in some countries, such as Japan, primarily for lung cancer treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were assessed in adult Japanese patients with advanced non-small cell lung cancer and small cell lung cancer following intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01DB10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Amrubicin;
